Latest Articles

Publication Date
Pharmacogenomic analysis of alarelin acetate-induced hepatotoxicity: a case report and literature review.

Alarelin acetate, a synthetic gonadotropin-releasing hormone (GnRH) analogue, is widely used to manage endometriosis and hormone-sensitive malignancies. Although its safety profile is generally favorable, we report the first documented case …

Published: Sept. 29, 2025, midnight
Erythema ab igne-A Potential Cutaneous Marker of Chronic Heat Use in Patients with Endometriosis: A Narrative Literature Review and a Case Report.

Erythema ab igne (EAI), also known as "hot water bottle rash" or "toasted skin syndrome", is a benign cutaneous condition caused by chronic exposure to low-level infrared heat. It typically …

Published: Sept. 29, 2025, midnight
Resection of Bilateral Endometriosis of the Uterosacral Ligaments Resolves Voiding Dysfunction: A Case Report.

Patients with deep endometriosis of the posterior pelvic compartment might present various lower urinary tract symptoms, including urinary retention, without any prior pelvic surgery in their medical history. These symptoms, …

Published: Sept. 29, 2025, midnight
Clinicopathological Characteristics and Oncologic Outcomes of Endometrioid Ovarian Carcinoma: A Retrospective Study from a Tertiary Cancer Centre.

Background/Objectives: To evaluate the clinicopathological features, treatment, and survival outcomes and to identify independent prognosticators for recurrence and mortality in patients with endometrioid ovarian cancer. Methods: The medical records of …

Published: Sept. 28, 2025, midnight
Top 10 priorities for future ectopic pregnancy research: an international consensus development study.

To determine the future priorities for ectopic pregnancy research.

Published: Sept. 27, 2025, midnight
Depo Provera Lawsuit Settlement | Sept 2025 Litigation Update - Lawsuit Information Center

Depo Provera Lawsuit Settlement | Sept 2025 Litigation Update Lawsuit Information Center

Published: Sept. 26, 2025, 5:53 p.m.
Ananda Pharma ends epilepsy trials, shifts focus to endometriosis drug By Investing.com - Investing.com Australia

Ananda Pharma ends epilepsy trials, shifts focus to endometriosis drug By Investing.com Investing.com Australia

Published: Sept. 26, 2025, 11:03 a.m.
Ananda Pharma ends epilepsy trials, shifts focus to endometriosis drug By Investing.com - Investing.com South Africa

Ananda Pharma ends epilepsy trials, shifts focus to endometriosis drug By Investing.com Investing.com South Africa

Published: Sept. 26, 2025, 10:56 a.m.
Ananda Pharma ends epilepsy trials, shifts focus to endometriosis drug - Investing.com India

Ananda Pharma ends epilepsy trials, shifts focus to endometriosis drug Investing.com India

Published: Sept. 26, 2025, 10:48 a.m.
Ananda Pharma ends epilepsy trials, shifts focus to endometriosis drug - Investing.com

Ananda Pharma ends epilepsy trials, shifts focus to endometriosis drug Investing.com

Published: Sept. 26, 2025, 10:25 a.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!